NOT-HL-20-783: Notice of Change in Application Due Date for RFA-HL-21-011, Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for HLB Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required)

Notice of Change in Application Due Date for RFA-HL-21-011, Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for HLB Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required)

Notice Number:

NOT-HL-20-783

Key Dates

Release Date:

April 30, 2020

Related Announcements

RFA-HL-21-011 Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required)

Issued by

National Heart, Lung, and Blood Institute (NHLBI)

Purpose

The Purpose of this notice is to inform potential applicants that a second application due date of July 1, 2020has been added for RFA-HL-21-011 Stimulating T4 Implementation Research to Optimize Integration of Proven-effective Interventions for Heart, Lung, and Blood Diseases and Sleep Disorders into Practice (STIMULATE-2) (R61/R33 Clinical Trial Required) . . Scientific Merit Review, Advisory Council Review, and Earliest Start Date remain unchanged.

The following section of RFA-HL-21-011 hasbeen updated to reflect the additional application due date:

Part 1. Overview Information

Key Dates

Currently reads:

Application Due Date(s)

May 1, 2020

Expiration Date

May 2, 2020

Modified to read:

Application Due Date(s)

May 1, 2020; July 1, 2020

Expiration Date

July 2, 2020

All other aspects of the FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Rebecca A. Roper, MS, MPH
National Heart, Lung, and Blood Institute (NHLBI)
Telephone: 301-496-1051
Email: [email protected]